



4<sup>TH</sup> IMMUNOTHERAPY  
OF CANCER CONFERENCE



Presented by CDDF in collaboration with SITC:

# THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE

## FINAL PROGRAMME

20 | MARCH  
22 | 2017

PRAGUE  
CZECH REPUBLIC



5<sup>TH</sup> Immunotherapy Of Cancer Conference

# THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE



MARCH 19-21, 2018



BERLIN, GERMANY



[www.itoc-conference.eu](http://www.itoc-conference.eu)



5<sup>TH</sup> IMMUNOTHERAPY  
OF CANCER CONFERENCE



5<sup>TH</sup> EDITION  
MARCH 19-21, 2018  
BERLIN, GERMANY


## SAVE THE DATE

## TABLE OF CONTENTS

WELCOME LETTER	PAGE 4
CANCER DRUG DEVELOPMENT FORUM & PARTNERS	PAGE 5
ORGANISING PARTNERS	PAGE 5
CONFERENCE COMMITTEE	PAGE 6
ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME)	PAGE 6
PROGRAMME AT A GLANCE	PAGE 7
SCIENTIFIC PROGRAMME	PAGE 8
POSTERS	PAGE 10
FLOORPLAN	PAGE 13
ACKNOWLEDGMENTS	PAGE 14
EXHIBITORS	PAGE 15
PARTNERS	PAGE 16
GENERAL INFORMATION	PAGE 17
CORPORATE SATELLITE SYMPOSIUM	PAGE 21



4<sup>TH</sup> IMMUNOTHERAPY  
OF CANCER CONFERENCE



## WELCOME LETTER

Welcome to the fourth edition of the Immunotherapy of Cancer conference (ITOC4), the premier meeting for education, scientific exchange and networking within cancer immunotherapy.

This meeting has been growing rapidly into a global platform for translational research in the field of immuno-oncology.

The scientific programme with an international faculty will focus on many topics such as Preclinical models, Micro-environment and Immune Regulation, Emerging concepts and novel targets, Combination therapy, Monitoring of immune response in the clinic, Therapeutic antibodies and Cell therapy.

Organised by the Cancer Drug Development Forum (CDDF), whose mission is to provide a unique platform to facilitate interactions between all stakeholders (academia, regulatory authorities, policymakers, industry, patient advocacy groups and health technology assessors) to improve the efficiency of cancer drug development and in cooperation with Society for Immunotherapy of Cancer (SITC), the ITOC conference series aim to provide a forum for discussion of early clinical drug development and address its unique challenges.

The conference offers a broad and exciting range of opportunities and tools to gain exposure to experts in various disciplines within Europe and far beyond, and we wish you a very successful and enjoyable ITOC-4 in the beautiful city of Prague.

In addition, we wish to express our sincere gratitude to the entire committee, organising partners and sponsors and exhibitors.

Your ideas and suggestions on the future of this conference are welcome. We therefore encourage you to complete the evaluation form at the end of the conference and please do not hesitate to reach out to our team on site or via email ([itoc@medacad.org](mailto:itoc@medacad.org))

Yours sincerely,

**Prof. Christoph Zielinski**  
Conference President

**Prof. Howard Kaufman**  
Conference President

**Prof. Volkmar Nüssler**  
Munich Tumour Center

**Prof. Heinz Zwierzina**  
Scientific Chairman

## CANCER DRUG DEVELOPMENT FORUM



The Cancer Drug Development Forum (CDDF) is a not-for-profit organisation registered in Austria.

It was established in 2001 as Biotherapy Development Association (BDA) and changed name in 2014 to Cancer Drug Development Forum (CDDF).

While BDA's focus was initially around immunotherapy, in recent years the association has embraced all forms of cancer drug development and therefore wanted a name that better reflects the organisation's breadth of interests and activities.

CDDF provides a unique forum where all those dedicated to the development of cancer drugs can exchange expertise to find ways to expedite effective oncology drug development and delivery.

For the past 14 years, CDDF has strived to leverage the discussion of the most promising advances in oncology drug development, uniting experts from academia, pharmaceutical industry and regulatory authorities in the quest of overcoming the main challenges in cancer treatment.

Meeting reports and publications based on previous workshops and events are featured in some of the leading oncology journals. You may access CDDF's list of publications at: [www.cddf.org](http://www.cddf.org)

## ORGANISING PARTNERS



Society for Immunotherapy of Cancer



## ITOC4 POSTER PRIZE



We are proud to announce the ITOC 4 Poster Prize which will be awarded at the 4th Immunotherapy of Cancer Conference thanks to the generous support of the Tumor Center Munich.

Prizes will be awarded to the three best poster presentations. The winners will receive a certificate and a prize of EUR 1000,-/700,-/500,-.

Winners are selected by the scientific committee according to the following criteria:

- Scientific content/methodology
- Novelty and originality of research
- Ability of the author to present the poster in a concise and clear manner and to answer questions during the dedicated poster sessions.

### Posterreviewing-Committee:

- Chairman: Prof. Dr. Sebastian Kobold (Ludwig-Maximilians-Universität, Germany)
- Prof. Dr. Bernhard Fox (Providence Cancer Center, USA)
- Prof. Dr. Lubos Petruzela (Charles University, Czech Republic)
- Prof. Dr. Eric Tartour (Hôpital Européen Georges-Pompidou, France)

## CONFERENCE COMMITTEE

### CONFERENCE PRESIDENTS

- Christoph Zielinski (Medical University of Vienna, Austria)
- Howard L. Kaufman (Rutgers Cancer Institute of New Jersey, USA)

### CHAIRMAN OF THE SCIENTIFIC COMMITTEE

- Heinz Zwierzina (Innsbruck University, Austria)

### SCIENTIFIC COMMITTEE

- Paolo A. Ascierto (Istituto Nazionale Tumori, Italy)
- Lisa H. Butterfield (University of Pittsburgh, USA)
- Bernard A. Fox (Providence Cancer Center, USA)
- Leif G. Hakansson (Universitetssjukhuset Linköping, Sweden)
- Robert F. Hawkins (The Christie Hospital, United Kingdom)
- Samir N. Khleif (Georgia Regents University, United States)
- Sebastian Kobold (Ludwig-Maximilians-Universität, Germany)
- Zihai Li (Medical University of South Carolina, USA)
- Volkmar Nuessler (Munich Tumour Center, Germany)
- Lubos Petruzela (Charles University, Czech Republic)
- Jose Saro (Roche, Switzerland)
- Barbara Seliger (Martin Luther University Halle-Wittenberg, Germany)
- Wenru Song (Chinese American Hematology and Oncology Network, USA)
- Zhen Su (Merck KGaA, Germany)
- Mario Sznoł (Yale School of Medicine, USA)
- Eric Tartour (Hôpital Européen Georges-Pompidou, France)
- Rostislav Vyzula (Masaryk Memorial Cancer Institute, Czech Republic)

## ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME)



The 4<sup>th</sup> ImmunoTherapy of Cancer Conference, Prague, Czech Republic (March 20 – 22, 2017) has been granted 12 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

European Accreditation is granted by the EACCME in order to allow participants who attend the above mentioned activity to validate their credits in their own country.



# PROGRAMME AT A GLANCE

## Monday, March 20, 2017

9:00	Registration Opens
10:30 - 11:00	Welcome Address
11:00 - 12:50	Opening Plenary Symposium Preclinical models
12:50 - 14:00	Lunch
14:00 - 15:00	Satellite Symposium
15:00 - 15:30	Coffee Break
15:30 - 17:40	Plenary Symposium Micro-environment and Immune Regulation
17:40	Poster Viewing with Presenters (Topic 2)
18:30	Welcome Reception

## Tuesday, March 21, 2017

08:30 - 10:00	Plenary Symposium Emerging concepts and novel targets
10:30 - 11:00	Coffee Break
11:00 - 12:50	Plenary Symposium Combination therapy
12:50 - 14:00	Lunch
14:00 - 14:45	Lifetime Achievement Award
14:45 - 15:45	Plenary Symposium Monitoring of immune response in the clinic
15:45 - 16:15	Coffee Break
16:15 - 17:25	Plenary Symposium Monitoring of immune response in the clinic (cont.)
17:30 - 18:15	Poster Viewing with Presenters (Topics 1,3,4,5,6)
19:30	ITOC4 Conference Dinner

## Wednesday, March 22, 2017

08:30 - 09:30	Plenary Symposium: Treatment of Immune Excluded and Immune Desert Tumor
09:30 - 10:30	Plenary Symposium Therapeutic antibodies
10:30 - 11:00	Coffee Break
11:00 - 12:10	Plenary Symposium Cell therapy
12:15	Best Poster Awards & Closing Remarks
12:45 - 13:30	Lunch

# SCIENTIFIC PROGRAM

## MONDAY, MARCH 20, 2017

10.30 - 11.00

### Welcome Address

Christoph Zielinski, Vienna, Austria

11.00 - 12.50

### Opening Plenary Symposium - Preclinical models and translational research

Chair: Howard Kaufman, New Brunswick, NJ, USA - Heinz Zwierzina, Innsbruck, Austria

11.00 - 11.10

### Welcome Address

11.10 - 11.40

### The need for preclinical models for immunotherapy

Mario Sznol, New Haven, CT, USA

11.40 - 12.00

### Preclinical and early clinical development of an autophagosome vaccine using immunomonitoring and genomics data

David Page, Portland, OR, USA

12.00 - 12.20

### Multispectral imaging of the tumour environment

Bernard A. Fox, Portland, OR, USA

12.20 - 12.35

### Tumor regression induced by type I interferon triggering in mammary tumor-bearing mice

Nadege Bercovici, Paris, France (A9)

12.35 - 12.50

### Small-molecule inhibitors of ecto-nucleotidase CD73 result in strong activation of human and mouse CD8+ T cells in the presence of exogenous AMP, affect tumor growth and positively affect anti-tumor immunity in mouse syngeneic tumor models

Annette Becker, Hayward, CA, USA (A21)

12.50 - 14.00

### Lunch

14.00 - 15.00

### Satellite Symposium – For further information please see page 21

15.00 - 15.30

### Coffee Break

15.30 - 17.40

### Plenary Symposium - Micro-environment and Immune Regulation

Chair: Bernard A. Fox, Portland, OR, USA - Leif Hakansson, Linköping, Sweden

15.30 - 15.50

### Targeting immunosuppressive enzymes in the tumor microenvironment

Benoit van den Eynde, Brussels, Belgium

15.50 - 16.10

### Overcoming metabolic barriers to antitumor immunity

Greg M. Delgoffe, Pittsburgh, PA, USA

16.10 - 16.30

### Mechanisms of exhaustion in T-Cells and tumor microenvironment

Ignacio Melero, Navarra, Spain

16.30 - 16.50

### Control of regulatory T cell function

Zihai Li, Charleston, SC, USA

16.50 - 17.10

### NK cells in the tumor microenvironment - implications for therapy

Lorenzo Moretta, Rome, Italy

17.10 - 17.25

### Monocytic myeloid derived suppressor cells (mMDSC) determine outcome in ovarian cancer

Thais Baert, Leuven, Belgium (A17)

17.25 - 17.40

### A predictive PD-L1\*CD8 cell density score for NSCLC patients treated with Durvalumab

Andreas Spitzmüller, Munich, Germany (A3)

17.40

### Postviewing with Presenters (Topic 2)

18.30

### Welcome Reception

## TUESDAY, MARCH 21, 2017

08.30 - 10.00

### Plenary Symposium - Emerging concepts and novel targets

Chair: Samir Khleif, Augusta, GA, USA - Wenru Song, Arlington, MA, USA

08.30 - 09.00

### Novel targets and approaches for immunotherapy development

Aurélien Marabelle, Paris, France

09.00 - 09.20

### Targeting CCR5 for macrophage repolarization for cancer immunotherapy

Niels Halama, Heidelberg, Germany

09.20 - 09.40

### Vaccination during myeloid cell depletion

Marij Welters, Leiden, Netherlands

09.40 - 10.00

### Therapeutic targeting of B cells

Michael von Bergwelt-Baildon, Cologne, Germany

10.00 - 10.15

### A tumor mitochondria vaccine protect against experimental renal cell carcinoma

Andrea Facciabene, Philadelphia, PA, USA (B1)



10:15 - 10:30

**In vivo targeting of TGF-beta inhibitors to CD8+ T cells via ultra-small amphiphilic Nanoparticles**

Sabrina Yu-Sang Yang, Cambridge, MA, USA (A36)

10:30 - 11:00

Coffee Break

11:00 - 12:50

**Plenary Symposium - Combination therapy**

Chair: Zihai Li, Charleston, SC, USA - Paolo Ascierto, Naples, Italy

11:00 - 11:20

**Combination of Check Point Blockade for Cancer Therapy**

Patrick A. Ott, Boston, MA, USA

11:20 - 11:40

**Combining vaccination with inhibition of T cell signaling**

Samir Khleif, Augusta, GA, USA

11:40 - 12:00

**Dendritic cell therapy in combination with checkpoint inhibition**

Bart Neyns, Brussels, Belgium

12:00 - 12:20

**Immunogenic chemotherapy**

Angus Dalglish, London, United Kingdom

12:20 - 12:35

**89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: role of IL-2 receptor-binding and CEA-mediated tumor accumulation in a dose-dependent manner**

C. Willemien Menke-van der Houven van Oordt, Amsterdam, Netherlands (B2)

12:35 - 12:50

**Doxorubicin loaded immunoliposomes coupled to anti-MAGE A1 TCR-like scFv for improved drug delivery to melanoma**

Mesha Saeed, Rotterdam, Netherlands (A40)

12:50 - 14:00

Lunch

14:00 - 14:45

**Lifetime Achievement Award**
**Cancer immunotherapy: the narrow road between inefficacy and toxicity**

Thierry Boon, Brussels, Belgium

14:45 - 17:25

**JOINT ESMO- ITOC Session**
**Plenary Symposium - Monitoring of immune response in the clinic**

Chair: Eric Tartour, Paris, France - Christoph Zielinski, Vienna, Austria

14:45 - 15:05

**Epigenetic immunomodulation for cancer immunotherapy**

Michele Maio, Siena, Italy

15:05 - 15:25

**Are immune-mediated adverse events really autoimmunity?**

Paolo Ascierto, Naples, Italy

15:25 - 15:45

**Prognostic and predictive value of multiplex in situ immunofluorescence in oncology**

Eric Tartour, Paris, France

15:45 - 16:15

Coffee Break

**Plenary Symposium - Monitoring of immune response in the clinic (cont.)**

16:15 - 16:35

**Identification of biomarkers using combined proteomic and genomic approaches**

Graham Ball, Nottingham, United Kingdom

16:35 - 16:50

**An Immunoinformatics Framework for Identification of Personalized Tumor Epitopes in Cancer**

Tanushree Jaitly, Erlangen, Germany (A46)

16:50 - 17:10

**Proteomic test identifies sensitivity and resistance to immunotherapy in cancer Patients**

Jeffrey Weber, New York, NY, USA (A31)

17:10 - 17:25

**Baseline peripheral blood biomarkers predict clinical outcome of advanced melanoma patients treated with ipilimumab: single institution real-life data experience**

Lenka Zdrazilova-Dubska, Brno, Czech Republic (A34)

17:30 - 18:15

**Posterviewing with Presenters (Topics 1, 3, 4, 5, 6)**

19:30

ITOC4 Conference Dinner

**WEDNESDAY, MARCH 22, 2017**

08:30 - 09:30

**Treatment of Immune Excluded and Immune Desert Tumors**

Chair: Paolo Ascierto

08:30 - 08:50

**The role of Batf-3 DC in the non-T cell-inflamed tumor microenvironment**

Stefani Spranger, Cambridge, MA USA

08:50 - 09:10

**Challenges and Opportunities for Reprogramming the Tumor Microenvironment**

Lei Zheng, Baltimore, MD, USA

09:10 - 09:30

**Combinatorial Immunotherapy and Anti-Angiogenic Approaches**

Lana Kandalaft, Lausanne, Switzerland

09:30 - 10:30

**Plenary Symposium - Therapeutic antibodies**

Chair: Sebastian Kobold, Munich, Germany - Barbara Seliger, Halle, Germany

09:30 - 09:50

**Tumour targeting antibodies: from tumor killing to immunity triggering**

*Yang Xin Fu, Dallas, TX, USA*

09:50 - 10:10

**Translating inhibitory Fc receptor biology into novel therapeutic approaches**

*Frank Nimmerjahn, Erlangen, Germany*

10:10 - 10:25

**Anti-proliferative & pro-apoptotic effects induced by simultaneous inactivation of HER1 & HER2 through endogenous polyclonal antibodies**

*Narjara González Suárez, Havana, Cuba (A43)*

10:30 - 11:00

Coffee Break

11:00 - 12:10

**Plenary Symposium - Cell therapy**

*Chair: Robert Hawkins, Manchester, United Kingdom – Stefan Endres, Munich, Germany*

11:00 - 11:30

**T-cell therapy - what have we learned about the role of Pre-conditioning chemotherapy and cytokines support?**

*Robert Hawkins, Manchester, United Kingdom*

11:30 - 11:50

**Editing of neoepitopes during T cell therapy**

*Els Verdegaal, Leiden, Netherlands*

11:50 - 12:10

**A novel platform for MHC-unrestricted adoptive T cell therapy**

*Sebastian Kobold, Munich, Germany*

12:15

**Best Poster Awards & Closing Remarks**

12.45 - 13.30

Lunch

## POSTER PRESENTATIONS

### 1. PRECLINICAL MODELS

**A1 Intratumoral immunotherapy. B16-F10 murine melanoma model**

*Jan Ženka, České Budějovice, Czech Republic*

**B3 Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo**

*Tomokazu Aoki, Kyoto, Japan*

**A2 Assessing humanized mouse models for cancer immunotherapy**

*Laure Loumagne, Vitry, France*

**A4 The influence of specific cytokines on cancer microtissue infiltrating cytotoxic T lymphocyte subpopulations**

*Stefan Koeck, Innsbruck, Austria*

**A5 A strategy to improve the translational impact of murine high grade glioma**

*Matteo Riva, Leuven, Belgium*

**A6 Genomic profiling and in vitro screen of syngeneic mouse cell lines testing checkpoint inhibitors in combination with targeted agents in a coculture system with mouse T cells**

*Frank Xing, Taicang, Jiangsu, China*

**A7 Doxorubicin increases TLR4 triggered activation marker on dendritic cells independent of exCalcium and the inflammasome**

*Dagmar Quandt, Halle, Germany*

**A8 Immunomodulatory Kits do not induce AML-blasts' proliferation ex vivo: IPO-38 is an appropriate and reliable marker to detect and quantify proliferating blasts**

*Caroline Plett, Munich, Germany*

**LB1 Immunotherapy targeting RIG-I in a mouse model of acute myeloid leukemia**

*Michael Ruzicka, Munich, Germany*

### 2. TUMOR IMMUNITY AND MICROENVIRONMENT

**B4 Immunomonitoring of the patients with colorectal cancer**

*Jan Spacek, Prague, Czech Republic*

**A10 A new method to generate mature (leukemia-derived) dendritic cells that improve antileukemic T-cell reactivity from mononuclear cells or whole blood from healthy volunteers or patients with AML**

*Daniel Amberger, Munich, Germany*

**A11 Interleukin-22 (IL-22) does not influence methycholanthren-A-mediated tumorigenesis**

*Anamarija Markota, Munich, Germany*

**A12 Inhibition of CD39 and CD73 by 3rd generation antisense oligonucleotides to improve immunity against tumors**

*Tamara Hilmenyuk, Planegg/Martinsried, Germany*

**A13 The immunome in early stage NSCLC: flow cytometry analyses of immunological subpopulations in tumor, lung tissue and whole blood**

*Gabriele Gamerith, Innsbruck, Austria*

**A14 Mitochondrial mass analysis in CD8+ T cells from lung cancer patients**

*Heriberto Prado-Garcia, Mexico City, Mexico*

**A15 Targeting hIDO1 with 3rd generation antisense oligonucleotides for modulation of the tumor microenvironment**

*Richard Klar, Martinsried, Germany*

**A16 Relevance of systemic immunosuppression in ovarian cancer patients**

*An Coosemans, Leuven, Belgium*

**B5 Profiling Compounds in Human Primary Cell BioMAP® Systems for Drug Discovery and Development in Cancer Immunotherapy**

*Alexander Baumann, Birmingham, United Kingdom*

**A18** GBP1 expression in colorectal cancer liver metastasis associates with increased CD8+ lymphocyte invasion and confers better prognosis

*Johannes Laengle, Vienna, Austria*

**B6** CCR4 activated by TNF- $\alpha$  facilitate metastasis via ERK/NF- $\kappa$ B pathway in colon cancer

*Xiaohui Shen, Shanghai, China*

**A19** Circulating myeloid-derived suppressor cells (MDSC) are increased in breast and colorectal cancer patients

*Lenka Zdrzilova-Dubska, Brno, Czech Republic*

**A20** Gene expression profile of the tumor microenvironment from 40 NSCLC FFPE and matched fresh frozen samples using a targeted NGS solution

*Chris Allen, South San Francisco, United States*

**B7** Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sections

*Bjoern Wendik, Rodgau, Germany*

**A22** Aberrant status of glutathione metabolism predict prognosis of colorectal cancer patients

*Shuai Yin, Muenchen, Germany*

**A23** Gastric cancer with lymphoid stroma: A study of clinico-pathological profile, Epstein-Barr virus, microsatellite instability, tumour immune microenvironment and PD-L1 status

*Irene Gulla, Porto, Portugal*

**A24** Asunercept (APG101) a CD95L-neutralizing compound protects immune cells from activation-induced cell death without compromising their anti-tumour activity

*Christian Merz, Heidelberg, Germany*

**A25** Recognition of tumor-associated self-protein Her2 by T cells of breast cancer patients and healthy donors

*Mariana Pinho, São Paulo, Brazil*

**A26** Effects of neoadjuvant chemotherapy on immune cell subsets in patients with breast cancer: A transcriptomic and phenotypic analysis

*Stephanie McArdle, Nottingham, United Kingdom*

**A27** Digital Pathology - a Key to Discover new Biomarkers?

*Carol Immanuel Geppert, Erlangen, Germany*

**A28** Glucocorticoid receptor agonist-mediated induction of miRNA-708 modulates breast cancer proliferation and metastasis via NF- $\kappa$ B signaling pathway

*Kj Senthil Kumar, Taichung, Taiwan*

**A29** Hexavalent CD27 agonist HERA-CD27L enhances anti-tumour response of effector T-cells in syngeneic mouse models of colorectal cancer

*Christian Merz, Heidelberg, Germany*

**LB2** Immune-related effects of the fat in ovarian cancer

*Meggy Suarez-Carmona, Heidelberg, Germany*

### 3. THERAPEUTIC MODULATION AND MONITORING OF IMMUNE RESPONSE

**A30** MuScreen<sup>TM</sup> : a panel of well-characterized syngeneic models for in vivo screening in a high-efficient manner

*Lan Zhang, Taicang, China*

**A32** Number, composition and/or antileukemic activity of (DC-stimulated) invariant NKT-, NK- and CIK-cells is predictive for outcome of patients with AML, ALL and CLL

*Corinna Boeck, Munich, Germany*

**A33** Clinical Experience of Nivolumab as a Second Line Treatment of Non-Small Cell Lung Cancer

*Young-Chul Kim, Jeonnam, Republic of Korea*

**B8** Therapeutic effect of immune reaction due to cryoablation

*Shinji Osada, Gifu, Japan*

**A35** HMGB1 plasma concentrations are associated with overall survival in lung adenocarcinoma patients

*D Aguilar-Cazares, Mexico City, Mexico*

**LB4** Pretreatment Immune Status is a prediction marker of progression-free survival in chemotherapy treated metastatic colorectal cancer patients

*Yuji Heike, Tokyo, Japan*

### 4. COMBINATION THERAPY

**B9** The significance of histopathological evaluation of pancreatic fibrosis to estimate pancreas cancer progression

*Shinji Osada, Gifu, Japan*

**A37** The dSLIM family of TLR9 agonists - benefit of the combination with checkpoint inhibitors in tumor models

*Barbara Volz, Berlin, Germany*

**A38** Study of immunogenic cell death markers in lung adenocarcinoma cell lines treated with therapeutic agents

*Rodolfo Chavez-Dominguez, Mexico City, Mexico*

**A39** Complete response of stage IIIB esophageal cancer combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia

*Ralf Kleef, Vienna, Austria*

**A41** Synergistic effects of P2X7 and doxorubicin in tumor cells

*Sana Javed, Hamburg, Germany*

**A42** Cancer immunotherapy with sequential administration of trabectedin and nivolumab in advanced soft tissue sarcoma

*Erlinda Gordon, Santa Monica, United States*

**B10** Radiation recall pneumonitis induced by double immune checkpoint blockade

*Petr Hausner, Baltimore, United States*

## 5. ANTI-CANCER VACCINES

- A44** Development of a novel immunotherapy with Toll-like and Nod-like receptors synergy for targeted cancer therapy

*Célia Jacobberger-Foissac, Illkirch, France*

- A45** Phase I clinical study for validation of photochemical internalisation (fimaVacc) - a novel technology for enhancing cellular immune responses important for therapeutic effect of peptide- and protein based vaccines

*Tone Otterhaug, Oslo, Norway*

## 6. ADOPTIVE CELL THERAPY

- A47** Preclinical characterization of a PD-1-CD28 fusion receptor for T cell-based immunotherapy of Non-Hodgkin Lymphoma

*Felicitas Rataj, Munich, Germany*

- B11** Arming T cells with activating FcγRIIIa receptors for antibody redirected lysis of cancer cells

*Felicitas Rataj, Munich, Germany*

- A48** Dominant negative tumor growth factor beta receptor 2 enables T cell activity in a murine pancreatic tumor model

*Bruno Loureiro Cadilha, München, Germany*

- LB5** Detection of highly prevalent and functional LAA-specific cytotoxic T lymphocytes in healthy Individuals implicates new strategies for adoptive t cell therapy of relapsed leukemia

*Sarah Matko, Dresden, Germany*

# FLOORPLAN - LEVEL 2 - PCC



Poster boards:

Topic 1. Preclinical models	= 9 Posters
Topic 2. Tumor Immunity and Microenvironment	= 23 Posters
Topic 3. Therapeutic modulation and monitoring of immune response	= 7 Posters
Topic 4. Combination therapy	= 7 Posters
Topic 5. Anti-cancer vaccines	= 2 Posters
Topic 6. Adoptive cell therapy	= 4 Posters
TOTAL = 52 Posters	

# ACKNOWLEDGMENTS

## SPONSORS-EXHIBITORS-PARTNERS

For questions regarding sponsorship and exhibition, please contact Rose International.



- Contact: Flora van Laer
- E-mail: fvanlaer@rose-international.com
- Telephone: +31 70 383 89 01

### We thank all ITOC4 sponsors and partners.

The ITOC4 Organising Committee wishes to gratefully acknowledge our sponsors and exhibitors for supporting the 4<sup>th</sup> Immunotherapy of Cancer Conference (ITOC4).

## SPONSORS



Bristol-Myers Squibb

### BRISTOL-MYERS SQUIBB

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of people around the world in their fight against cancer, cardiovascular disease, hepatitis C, HIV and rheumatoid arthritis.

⊕ [View more on www.bms.com](http://www.bms.com)



### INCYTE CORPORATION

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. World-class science and the pursuit of R&D excellence drive Incyte's business and its commitment to improving the lives of patients with cancer and other diseases. Incyte has a broad and diverse clinical portfolio that includes 14 development candidates against 11 different molecular targets.

⊕ [View more on www.incyte.com](http://www.incyte.com)



### LILLY ONCOLOGY

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world.

⊕ [To learn more about Lilly's commitment to people with cancer, please visit www.lillyoncology.com](http://www.lillyoncology.com)



### MILTENYI BIOTEC

Miltenyi Biotec provides products that advance biomedical research and cellular therapy. Our innovative tools support research from basic research to translational research to clinical application. Our more than 25 years of expertise includes immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has more than 1,700 employees in 25 countries.

⊕ [View more on www.miltenyibiotec.com](http://www.miltenyibiotec.com)



### NANOSTRING

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter<sup>®</sup> Analysis System, which has been employed in basic and translational research and cited in 1,000+ peer review publications, has also now been applied to diagnostic use with the nCounter Dx Analysis System. The nCounter-based Prosigna<sup>™</sup> Breast Cancer Prognostic Gene Signature Assay is marketed for use on the nCounter Dx Analysis System which is FDA 510(k) cleared.

⊕ [View more on www.nanostring.com](http://www.nanostring.com)



### THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.

⊕ [View more on www.thermofisher.com](http://www.thermofisher.com)



**MSD**

For over a century, MSD has been a global health care leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., Kenilworth, N.J., USA. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit [www.msd.com](http://www.msd.com) or [www.msd.XX](http://www.msd.XX) (for country-specific website).

⊕ visit [www.msd.com](http://www.msd.com) or [www.msd.XX](http://www.msd.XX) (for country-specific website)

**EXHIBITORS****ACRIS ANTIBODIES**

Acris Antibodies acquired by OriGene recently, offer > 1 million research products – everything you need for gene and protein based research: cDNA clones, siRNA, lysates, proteins, antibodies and many more. Acris Antibodies- OriGene EU is your “1 stop solution provider”. We support you as cancer research scientists in your gene as well as protein directed approaches.

⊕ View more on [www.acris-antibodies.com](http://www.acris-antibodies.com)

Aquila BioMedical

**AQUILA BIOMEDICAL**

Aquila BioMedical is an innovative, preclinical contract research organisation, offering clients world-leading research expertise in immuno-oncology, immunology and multiplex histology. We offer bespoke services, combining advanced models with protocolled techniques. The result? High-value data allowing you to define efficacy and mechanism of action of drug/antibody candidates. Partner with us to benefit from expert advice and data interpretation from superior and experienced scientists.

⊕ View more on [www.aquila-bm.com](http://www.aquila-bm.com)

**BIOLEGEND**

BioLegend develops and manufactures world-class, cutting-edge antibodies and reagents at an outstanding value. The broad product portfolio includes flow cytometry, cell biology, and functional reagents for research in immunology, neuroscience, cancer, and stem cells. Custom services include assay development, sample testing, and conjugation. BioLegend is certified for ISO 9001:2008 and ISO 13485:2003.

⊕ View more on [www.biolegend.com](http://www.biolegend.com)

**THE CANCER DRUG DEVELOPMENT FORUM (CDDF)**

CDDF looks forward to welcoming you at the 4th edition of the Immunotherapy of Cancer Conference (ITOC4) in Prague. We will be available to meet you at the exhibition area, feel free to come and visit us at any time! The (CDDF) is an international organization providing a platform for all stakeholders involved in the development of oncology drugs. The aim of the not-for-profit organization is to accelerate the delivery of effective oncology agents to patients.

⊕ View more on <http://cddf.org> or [twitter cddf\\_eu](https://twitter.com/cddf_eu)

**CROWN BIOSCIENCE**

Crown Bioscience, Inc. is a platform technology company providing drug discovery and development services in Oncology and Metabolic Disease. Our unique collection of ready-to-run, well-validated in vitro, in vivo, ex vivo models, comprehensive Translational Platform, and immunotherapy models including syngeneic and humanized systems, enable clients to deliver superior clinical candidates.

⊕ View more on [www.crownbio.com](http://www.crownbio.com)

**DISCOVERX**

DiscoverX Corporation is the leading supplier of innovative cell-based assays and services for drug discovery and development. The industry-leading portfolio of products and services, under the KINOMEScan®, PathHunter® and BioMAP® brands, enables rapid development of safe and effective biologic and small molecule drugs from early discovery through preclinical development.

⊕ View more on [www.discoverx.com](http://www.discoverx.com)

**IMMUDEX**

Based in Copenhagen, Denmark, Immudex manufactures MHC Dextramers for the detection of antigen-specific T cells in life science research, in vitro diagnostics, and the development of immunotherapeutics and vaccines. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.

⊕ View more on [www.immudex.com](http://www.immudex.com)



#### INCYTE CORPORATION

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. World-class science and the pursuit of R&D excellence drive Incyte's business and its commitment to improving the lives of patients with cancer and other diseases. Incyte has a broad and diverse clinical portfolio that includes 14 development candidates against 11 different molecular targets.

⊕ View more on [www.incyte.com](http://www.incyte.com)



#### MERCK-PFIZER ALLIANCE

Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other's strengths and capabilities and further explore the therapeutic potential of avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer's PD-1 antibody.

⊕ View more on [www.merckgroup.com](http://www.merckgroup.com)



#### MBL INTERNATIONAL

MBL International is a life science company focused on providing high quality, innovative, solutions-based products for life science research and clinical diagnostics. MBL develops and manufactures a broad portfolio of monoclonal and polyclonal antibodies, MHC tetramers, fluorescent and recombinant proteins and ELISA kits for research related to allergy, apoptosis, autophagy, cancer, epigenetics, immunology, and neuroscience.

⊕ View more on [www.mblintl.com](http://www.mblintl.com)



#### NANOSTRING

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter<sup>®</sup> Analysis System, which has been employed in basic and translational research and cited in 1,000+ peer review publications, has also now been applied to diagnostic use with the nCounter Dx Analysis System. The nCounter-based Prosigna<sup>™</sup> Breast Cancer Prognostic Gene Signature Assay is marketed for use on the nCounter Dx Analysis System which is FDA 510(k) cleared.

⊕ View more on [www.nanostring.com](http://www.nanostring.com)



#### PEPROTECH

PeproTech is a privately owned biotechnology company focusing on the development and manufacture of high quality cytokine products for the life-science and cell therapy market. With over 2,000 products PeproTech has developed and refined innovative protocols to ensure quality, reliability and consistency. We pride ourselves on being a trusted partner within the scientific community. Please contact: 020 7610 3062 or [info@peprotech.co.uk](mailto:info@peprotech.co.uk)

⊕ View more on [www.peprotech.com](http://www.peprotech.com)



#### THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC)

SITC is a 501 (c)(3) non-profit professional society of over 1,600 influential scientists and practitioners from around the world who are dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Through emphasis on high-caliber scientific meetings, education, and collaborations, SITC brings together all aspects of cancer immunology and immunotherapy.

⊕ View more on [www.sitcancer.org](http://www.sitcancer.org) or [sitcancer](https://twitter.com/sitcancer)



#### THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.

⊕ View more on [www.thermofisher.com](http://www.thermofisher.com)

### PARTNERS



#### THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC)

⊕ View more on [www.sitcancer.org](http://www.sitcancer.org)



#### THE CHINESE AMERICAN HEMATOLOGIST AND ONCOLOGIST NETWORK (CAHON)

For more information, please visit <http://cahon.org>



#### TUMORZENTRUM MÜNCHEN – TZM (MUNICH TUMOUR CENTRE)

⊕ View more on [www.tumorzentrum-muenchen.com](http://www.tumorzentrum-muenchen.com)

# GENERAL INFORMATION

## SECRETARIATS

### SECRETARIAT

#### The Cancer Drug Development Forum (CDDF)

Avenue E. Mounier 83  
1200 Brussels, Belgium  
Phone: +32 (0)2 775 02 15  
Email: [cddf@ecco-org.eu](mailto:cddf@ecco-org.eu)  
Website: [www.cddf.org](http://www.cddf.org)



### CONFERENCE MATTERS

#### Vienna Medical Academy

Contact: Catherine Tomek  
E-mail: [itoc@medacad.org](mailto:itoc@medacad.org)  
Telephone: +43 1 405 13 83 18



### SPONSORSHIP AND EXHIBITION MATTERS

#### Exhibition Management & Congress Consultancy bv

Contact: Flora van Laer  
E-mail: [fvanlaer@rose-international.com](mailto:fvanlaer@rose-international.com)  
Telephone: +31 70 383 8901



## CONFERENCE VENUE

### Prague Congress Centre

Exhibition Area: Forum Hall Foyer, level 2  
Address: 5. května 65 – CZ-14021 Prague, Czech Republic  
Telephone: +420 261 171 111  
[www.kcp.cz](http://www.kcp.cz)



## HOW TO REACH THE VENUE

The Prague Congress Centre is adjacent to the Vyšehrad station on Line C of the Prague underground railway network, providing convenient access by public transport from the city's airport and all major rail and bus stations.

For further information on public transportation please see: [www.kcp.cz/en/travel-to-pcc](http://www.kcp.cz/en/travel-to-pcc)



## REGISTRATION

### Registration Hours

- Monday, March 20, 2017 ..... 09:00 - 18:30 hrs
- Tuesday, March 21, 2017 ..... 07:30 - 18:30 hrs
- Wednesday, March 22, 2017 ..... 08:00 - 13:30 hrs

### Registration fees in Euro

Payment received:	Early Bird until December 15, 2016	December 16 to March 10, 2017	On-Site
Academia	450,-	550,-	650,-
Junior Participant <sup>1</sup>	120,-	150,-	175,-
Industry	750,-	850,-	950,-
SITC Members – Academia <sup>2</sup>	380,-	480,-	580,-
SITC Member – Junior Participant <sup>1,2</sup>	100,-	130,-	155,-
Press/Media Pass Registration <sup>3</sup>	Free of charge		
Welcome Reception for registered participants	No Fee, but registration is mandatory		
Conference Dinner for registered participants	65,-		

<sup>1</sup> The "Junior Participant" registration is available for Students under 30 years of age. Please provide a copy of a student ID at the moment of your registration.

<sup>2</sup> Please provide the SITC Promotional Code during on site registration. Note: the reduced registration fee only applies if the code is provided – make sure to inquire with SITC prior to your on site registration.

<sup>3</sup> A Press ID confirming your status must be provided at the moment of your registration.

### IMPORTANT:

**Reduced registration fees are only applicable, if they have been credited to the congress account before the respective deadlines. Registering before a deadline** without performing an actual payment was not sufficient to benefit from the reduction. Please note that a different fee applies for onsite payments and registrations. **If the fee is not transferred to the congress bank account before the respective deadline expires the fee will be changed to the next applicable fee automatically.**

### What is covered by the registration fee?

- Admission to all scientific sessions
- Abstract book and programme
- Welcome reception (no fee but registration mandatory)
- Coffee breaks & Lunches
- Admission to exhibition

### Cancellations

Please note that only written cancellations addressed to ITOC4 c/o Vienna Medical Academy, Alser Straße 4, 1090 Vienna, Austria either per E-Mail: itoc@medacad.org or Fax: +43 1 405 13 83 918 can be accepted.

The following rules apply:

- before January 31, 2017: 50% refund
- after January 31, 2017: no refund

### Replacements

Any replacement (i.e. change of delegate name) of a confirmed registration is subject to a 50 EUR charge per participant.

## BADGES

For security reasons, badges will be checked upon access of the conference areas. Delegates are therefore requested to wear their badge at all times during the conference.

## CATERING

Coffee breaks, lunches and a welcome reception have been scheduled. Exact times are listed in the programme overview.

## CERTIFICATE OF ATTENDANCE

The 4<sup>th</sup> ImmunoTherapy of Cancer Conference is happy to introduce a digital CME acquisition system. You will be able to view and print a confirmation stating the according number of CME credits after finishing a survey requested by the UEMS. The link to the survey will be sent to all registered participants right after the conference. It is possible to claim a maximum of 12 CME points for attendance of scientific sessions at the ITOC4.

## NETWORKING EVENTS

### Monday, March 20, 2017

Welcome Cocktail in the exhibition area of the Prague Conference Center

**No fee for registered participants, but registration is mandatory!**

### Tuesday, March 21, 2017

Conference dinner at the Sacré Coeur

Website: [www.sacrecoeur.cz](http://www.sacrecoeur.cz)

Contribution towards expenses: EUR 65,-



## EXHIBITION

The exhibition is held in the Forum Hall Foyer 2 of the Conference Center. Entrance is free for registered delegates but limited to healthcare professionals, press and exhibitors.

## INSURANCE

By registering to the ITOC4 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements for health and travel insurance. The conference fee does not include insurance.

## LANGUAGE & TRANSLATION

The official language of the conference is English. No simultaneous translation is provided.

## LOST & FOUND

All enquiries should be directed to the registration desk in the entrance hall of Level 2. The organizers accept no responsibility for loss due to theft or negligence.

## POLICIES

ITOC4 is accessible to all registered delegates. Children and members of the public are not permitted in the exhibition area or any room hosting an industry activity. In addition, the ITOC-4 conference asks delegates and faculty to refrain from taking children and accompanying adults to any sessions or practical demonstrations. In the event that children are required to enter the conference centre, they should be supervised by an adult at all times and observe the restrictions that apply to limited access areas. In the event that a member of public is invited to participate in the ITOC conference scientific programme, they should be accompanied by a qualified healthcare professional or ITOC representative observing the ITOC restrictions where appropriate.

SAVE THE DATE

CALL FOR  
ABSTRACTS  
SUBMISSION  
OPENS  
APRIL 3

SITC  
2017

November 8-12

NATIONAL HARBOR  
MARYLAND

Gaylord National Hotel  
& Convention Center



Society for Immunotherapy of Cancer

[sitcancer.org/](http://sitcancer.org/)

## Keynote Speaker

Paul M. Sondel, MD, PhD – *University of Wisconsin, Madison*

*2017 Richard V. Smalley, MD Memorial Award and Lectureship Recipient*





## Official ITOC4 Sponsored Satellite Symposium

# Cross-Disciplinary Insights and Emerging Tools of the Trade for Immuno-Oncology

Monday, 20 March 2017 | 14:00–15:00

Prague Congress Centre

Forum Hall

Prague, Czech Republic

### Programme:



#### PD-L1—Friend or Foe? A Pathologist's Perspective

*Aleš Ryška, MD, PhD*

*Charles University Medical Faculty and*

*University Hospital*

*Hradec Králové, Czech Republic*



#### A Radiation Oncologist's View of Immunotherapy

*David Feltl, MD, PhD, MBA*

*General University Hospital*

*Prague, Czech Republic*



#### The Role of Molecular Markers— A Medical Oncologist's Perspective

*Luboš Petruželka, MD, PhD*

*First Faculty of Medicine, Charles University and*

*General University Hospital*

*Prague, Czech Republic*

Meeting Chair

### Panel discussion and audience Q&A to follow presentations

Bristol-Myers Squibb: Official Sponsor

4th Immunotherapy of Cancer Conference (ITOC4)



## NOTES



# SEE WHAT INNOVATIONS IN IMMUNO-ONCOLOGY COULD MEAN FOR YOUR PATIENTS

Our research and development team takes a broad and integrated approach in the development of new immunotherapies. This approach involves leveraging an existing portfolio of molecules that target and modulate the immune-suppressive environment that surrounds tumors. Deep expertise in antibody technology and chemistry helps us develop molecules that effectively modulate T-cell function. We're also investigating novel approaches to redirect activated T cells to tumors.

To find out more about the immunotherapies we currently have in clinical development, please go to [www.Lilly.com](http://www.Lilly.com).





4<sup>TH</sup> IMMUNOTHERAPY  
OF CANCER CONFERENCE



20 | MARCH  
22 | 2017

PRAGUE  
CZECH REPUBLIC



Society for Immunotherapy of Cancer



 [www.itoc-conference.eu](http://www.itoc-conference.eu)